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Introduction
Atherosclerotic cardiovascular disease (ASCVD) is a major 
global cause of death (1, 2). Yet prevention of this disorder re-
mains suboptimal. The purpose of primary prevention is to de-
tect individuals who have high enough risk for cardiovascular 
events to warrant targeting them with intensive interventions 
that not only involve changes in lifestyle, but pharmacological 
approaches as well. 
Risk prediction models should have good discrimination 
power to be clinically meaningful. Numerous algorithms use 
combinations of conventional risk factors to identify individuals 
at higher risk for cardiovascular disease (CVD) who are most 
likely to benefit from preventive measures (3, 4). Both the Ameri-
can College of Cardiology/American Heart Association (ACC/
AHA) and the European Society of Cardiology (ESC) develop and 
continuously update their guidelines in order to influence clini-
cal practice. These guidelines use varying approaches to CVD 
risk estimation and implement different criteria for therapeutic 
recommendations. ESC advocates the use of the Systematic 
Coronary Risk Evaluation (SCORE) equation for individuals aged 
between 40 and 65 years. According to the ESC guideline, if the 
estimated 10-year risk of ASCVD ≥5% and low-density lipopro-
tein (LDL) cholesterol level ≥100 mg/dL, or the estimated 10-year 
risk of ASCVD≥10% and LDL cholesterol level ≥70 mg/dL, initia-
tion of a statin treatment is recommended for primary preven-
tion (5). Meanwhile, the ACC/AHA developed cardiovascular risk 
calculator targeting individuals between 40 and 75 years of age. 
According to the ACC/AHA guideline, if the estimated 10-year 
risk of ASCVD ≥7.5% or primary LDL cholesterol level ≥189 mg/
dL, initiation of a statin treatment is recommended for primary 
prevention (6). Different approaches to statin treatment translate 
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into substantial differences with respect to population qualify-
ing for treatment, economic burden and health systems. This 
study is a comparison of the ACC/AHA guideline with the ESC 
guideline for initiation of statin treatment for primary prevention 
of ASCVD in the Turkish population.
Methods
Study design
All consecutive patients aged between 40–75 years admit-
ted to Başkent University Ankara hospital on an outpatient ba-
sis between December 2013 and April 2014 were evaluated for 
possible enrollment in the study. The research was conducted in 
accordance with the Second Helsinki Declaration and was ap-
proved by the Local Ethics Committee. Patients without sufficient 
data in the records to calculate risk score, patients who had 
statin treatment indications for secondary prevention (presence 
of coronary artery disease, peripheral arterial disease, cerebro-
vascular disease, or diabetes mellitus) were excluded.
The records of 4533 patients were examined, 3700 patients 
were excluded from study, and the scores of 833 patients (482 
women and 351 men) were calculated (Fig. 1). Patients were di-
vided into 2 groups according to sex. Within each gender group, 
patients were subdivided into 4 groups according to age (40–49 
years, 50–59 years, 60–69 years, and 70–75 years). Risk scores 
were calculated according to both guidelines and indication for 
immediate statin treatment was determined. If 10-year score 
risk of ASCVD ≥5% and LDL cholesterol level ≥100 mg/dL, or the 
estimated 10-year score risk of ASCVD≥10% and LDL choles-
terol level ≥70 mg/dL, ESC recommends initiation of immediate 
statin treatment for primary prevention in individuals 40 to 65 
years of age (5). In the presence of the same other risk fac-
tors, the score risk of patients over the age of 65 was the same 
as those with the age of 65 . We used high-risk version of the 
SCORE scale in this study.
ACC/AHA targeted individuals aged between 40 and 75 years. 
According to the ACC/AHA guideline, if the estimated 10-year 
risk of ASCVD ≥7.5% or primary LDL cholesterol level ≥189 mg/
dL, initiation of an immediate statin treatment is recommended 
for primary prevention (6).
Statistical analyses
Variables are presented as mean±SD or median (range, in-
terquartile range [IQR]) for continuous data and as proportion for 
categorical data. Continuous variables with normal distribution 
were analyzed with unpaired t-test. Continuous variables with 
non-normal distribution were analyzed using Mann-Whitney 
U test. Kolmogorov-Smirnov test was used to identify whether 
continuous variables were normally distributed. Categorical pa-
rameters were analyzed with chi-square or Fischer’s exact test, 
as appropriate. Two-sided p values <0.05 were considered sig-
nificant. Statistical analysis was performed using commercially 
available computer program (SPSS version 21.0 for Windows; 
SPSS, Inc., Chicago, Illinois, US).
Results
We evaluated 833 patients (482 women and 351 men). Base-
line characteristics of the participants are presented in Table 1. 
When ACC/AHA risk score was considered, 415 patients out of 
833 (49.5%) were eligible for statin treatment, while this figure 
was 193 patients (23.1%) for the ESC SCORE system (p<0.001). 
We found that statins would be recommended for primary pre-
vention for 40.4% of women and 62.6% of men by the ACC/AHA, 
while this was 12% for women and 38.4% for men under the ESC 
guideline (p<0.001 for both). 
Based on ACC/AHA ASCVD risk score, median risk was 7.4% 
(0–48.6 ; IQR=9.8) for the overall study population (Fig. 2). Twenty-
six patients would be eligible for statin treatment based on LDL 
cholesterol over 189 mg/dL. There were 389 patients whose risk 
was ≥7.5% (median=13.3; 7.5–48.6; IQR=10.25), thus qualifying for 
statin treatment according to ACC/AHA guideline. Table 2 shows 
the number of individuals qualifying for statin treatment stratified 
by empiric 5-point increase in risk.
According to the ESC, median risk score for our population 
was 2% (0–33; IQR=3) (Fig. 3). Fifty-two patients qualified for 
statin treatment based on score risk of ≥5% and LDL cholesterol 
 4533 patients
  2402 women
  2131 men
 1262 patients missing data
  804 women
  458 men
 2021 patients CAD
  909 women
  1112 men
 266 patients DM
  136 women
  130 men
 102 patients CVD
  49 women
  53 men
 49 patients PAD
  22 women
  27 men
 3271 patients
  1598 women
  1673 men
 1250 patients
  689 women
  561 men
 984 patients
  553 women
  431 men
 882 patients
  504 women
  378 men
 833 patients
  482 women
  351 men
Figure 1. Recruitment protocol for the study population
CAD - coronary artery disease; CVD - cerebrovascular disease; DM - diabetes mellitus; PAD 
- peripheral arterial disease
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≥100 mg/dL. The total was 141 patients when risk score ≥10 and 
LDL cholesterol ≥70 mg/dL were considered.
There were also significant differences between the 2 
guidelines for 50–59 years and 60–69 years groups of female 
patients (p<0.001 for both). There were no statistically signifi-
cant differences in 40–49 years and ≥70 years groups (p=0.341 
and p=0.634, respectively). There were significant differences 
in 40–49 years and 50–59 years groups in male patients. There 
were no statistically significant differences in 60–69 years 
and ≥70 years groups in men (p=0.065 and p=0.99, respec-
tively) (Table 3).
Discussion
In this study, it was observed that compared with the ESC 
guideline, the ACC/AHA guideline would augment the number 
of individuals requiring statin treatment for primary prevention 
of cardiovascular disorders. ACC/AHA guideline would recom-
mend statins for almost all male patients and more than 70% of 
female patients age 70 years and over for primary prevention.
There are no considerable differences between the ACC/AHA 
guideline (6) and the ESC guideline with respect to recommen-
dations for statin use in secondary prevention (5). Selection of 
patients and determination of indications for statin use in primary 
prevention is a source of great debate. Different risk prediction 
systems exist for determination of patients at risk in primary pre-
vention. The most commonly used scoring systems are the risk 
scoring tools of the ACC/AHA guideline and the ESC guideline 
SCORE risk system. For primary CVD prevention, based on the 
evidence from clinical trials of statin drugs, the new ACC/AHA 
guideline modified clinical decision-making and proposed recom-
mending statin treatment solely based on a 10-year ASCVD risk 
greater than 7.5% (6). This distinction from previous guidelines in 
the United States and from current ESC guideline represents a 
fairly straightforward approach that deviates from risk functions 
of 10-year hard coronary heart disease (CHD) or CVD mortality 
combined with blood concentrations of LDL cholesterol (5, 7, 8).
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Table 1. Characteristics of the study population
Gender Women Men 
  (n=482) (n=351)
Age, years 58.1±9.3 55.3±9.2
Systolic blood pressure, mm Hg 142±24 145±26
Diastolic blood pressure, mm Hg 73±11 75±13
Antihypertensive treatment, n (%) 303 (62.9) 188 (53.6)
Current smoking, n (%) 70 (14.5) 93 (26.5)
Chronic kidney disease, n (%)  2 (0.4) 2 (0.6)
Total cholesterol, mg/dL 225±42 215±38.4
HDL cholesterol, mg/dL 51.5±10.9 45.4±9.01
LDL cholesterol, mg/dL 144±36.1 137.7±31.5
TG, mg/dL* 125 (93–165) 140 (102–193)
*Data expressed as median with interquartile range. HDL - high-density lipoprotein; 
LDL - low-density lipoprotein; TG - triglyceride
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Figure 2. The ACC/AHA calculated risk for the study population (n=833). 
X-axis represents percentage of risk
Table 2. Subjects qualifying for statin treatment based on ACC/AHA 
risk level
Stratified risk level* Patients n, (%)
7.5–12.4 177 (42.6)
12.5–17.4 86 (20.7)
17.5–22.4 59 (14.2)
≥22.5 67 (16.1)
  26 (6)**
*Five-point increase in the risk was chosen empirically for stratification. **Patients 
with LDL cholesterol >189 mg/dL. ACC/AHA - American College of Cardiology/Ameri-
can Heart Association; LDL - low-density lipoprotein
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Figure 3. The ESC calculated score risk for the study population (n=833). 
X-axis represents percentage of risk
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Usability of a risk prediction system depends on combination 
of its calibration and discrimination (9). Proper calibration of a 
risk prediction system is crucial when it is used to make a deci-
sion whether a treatment is to be initiated (9). An inaccurate risk 
prediction system may not only fail to correctly determine pa-
tients truly at risk, but may also lead to possible drug complica-
tions and unnecessary cost through improper patient selection. 
Kavousi et al. (8) showed that the 3 risk prediction systems (the 
ACC/AHA guideline, the National Cholesterol Education Program 
Adult Treatment Panel III, and the ESC guideline) provided poor 
calibration and moderate discrimination. This study showed that 
compared with the ESC guideline, the ACC/AHA guideline would 
increase the number of patients eligible for statins for primary 
and secondary prevention of cardiovascular disorders from 
66.1% to 96.4% in male patients and from 39.1% to 65.8% in fe-
male patients in the European cohort (8). Additionally, this study 
showed that the c-statistics values of the 3 risk prediction sys-
tems were not considerably different, although the ESC guide-
line’s risk prediction system still had the relatively highest value 
(8). Similarly, Vaucher et al. (10) concluded that, relative to the 
ESC guideline, the ACC/ AHA guideline leads to a considerable 
increase in the number of high-risk individuals for whom statin 
treatment would be recommended: 2.2 times more male patients 
and 1.9 times more female patients in Switzerland. Taylor et al. 
(11) and Mihaylova et al. (12) also reported in separate studies 
that the ACC/AHA guideline has a lower cut-off level for treat-
ment. In the present study, when compared to the ESC guideline, 
the ACC/AHA would increase the number of individuals qualify-
ing for statin treatment about 1.6 times in male patients and 3.36 
times in female patients for primary prevention. Our study further 
strengthens previous findings and showed that no women aged 
below 60 years would be qualified for statin treatment by the 
ESC guideline. Similarly, the Swiss data from Vaucher et al. (10) 
disclosed that no women below 60 years of age required statin 
treatment when the ESC guideline was observed. 
ESC recommends the use of the SCORE risk prediction sys-
tem for the evaluation of 10-year CVD risk, especially in Euro-
pean countries (5); ESC also recommends the use of a version 
of the SCORE system that was primarily designed for high-risk 
countries in central Europe, eastern Europe, former Soviet Union 
countries, and Turkey, although local data were not obtained 
from all of these countries during the development of that scor-
ing system (5, 13). Health, Alcohol and Psychosocial factors in 
Eastern Europe (HAPIEE) and Monitoring Cardiovascular disease 
(MONICA) trials that basis of the SCORE system demonstrated 
that different social and biological features of different European 
countries variably affect cardiovascular mortality, although nei-
ther of the 2 studies contained data from Turkey (14, 15).
There are considerable differences between the ACC/AHA 
guideline and the ESC guideline with regard to statin indications 
for primary prevention. There is a need for studies exploring the 
suitability of the risk prediction systems in the ESC and the ACC/
AHA guidelines for the Turkish population. It would be beneficial 
to develop a risk prediction system suited to genetic properties 
and specific risk factors of the Turkish population. In this way, it 
could be possible to determine patients for whom statin therapy 
is suitable based on specific properties of the society. It would 
also be possible to avoid unnecessary costs and minimize medi-
cation side effects.
Study limitations
There are some limitations to the present study. First, our 
study was not a follow-up study and it did not study calibration 
and discrimination of the guidelines in a Turkish population. Sec-
ond, cost analysis of both guidelines was not possible due to in-
complete study data. Third, it solely enrolled patients presenting 
at an outpatient clinic of a tertiary university hospital. Thus, the 
study population does not necessarily reflect the general Turkish 
population. 
Conclusion
Relative to the ESC guideline, the ACC/AHA guideline would 
lead to considerable increase in the number of individuals likely 
to receive statin treatment for primary prevention of cardiovas-
cular disorders in Turkish population.
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Table 3. Statin treatment recommendations of guidelines for different age and sex groups
   Male   Female   Total
Age, years ESC  ACC/AHA P ESC ACC/AHA P ESC ACC/AHA P 
  suggests suggests  suggests suggests  suggests suggests 
  statin statin  statin statin  statin statin 
  n (%) n (%)  n (%) n (%)  n (%) n (%)
40–49 (n=232) 4 (1.7) 33 (14.2) 0.016 0 (0) 6 (2.5) 0.341 4 (1.7) 39 (16.8) 0.004
50–59 (n=304) 46 (15.1) 81 (26.6) <0.001 0 (0) 39 (12.8) <0.001 46 (15.1) 120 (39.4) <0.001
60–69 (n=221) 67 (30.3) 87 (39.3) 0.065 38 (17.1) 94 (42.5) <0.001 105 (47.5) 181 (81.9) <0.001
≥70 (n=76) 18 (23.6) 19 (25) 0.99 20 (26.3) 56 (73.6) 0.634 38 (50) 75 (98.6) 0.484
ACC/AHA - American College of Cardiology/American Heart Association; ESC - European Society of Cardiology
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